Reclast (Zoledronic Acid) Pediatric Transition to Adult Care: What Families and Clinicians Need to Know

Why Transition Planning Matters for Young Patients on Zoledronic Acid

Zoledronic acid remains in bone tissue for years after the final infusion. A single annual dose of 0.05 mg/kg IV in a child can suppress bone resorption markers for 12 months or longer, and skeletal drug reservoirs may persist well beyond adolescence. When care transfers from a pediatric endocrinologist or metabolic bone specialist to an adult provider, gaps in that handoff can result in missed infusions, duplicated dosing, or failure to reassess whether treatment is still needed.

Pediatric osteoporosis is not a single disease. Children under 12 most commonly receive zoledronic acid for osteogenesis imperfecta (OI), glucocorticoid-induced osteoporosis, or secondary causes tied to chronic illness. Each of these underlying conditions follows its own adult trajectory, which means the adult provider inheriting the case must understand both the bone pharmacology and the primary diagnosis. The Endocrine Society's 2023 Clinical Practice Guideline on Pediatric Osteoporosis explicitly calls for individualized transition plans rather than automatic continuation of pediatric regimens.

The Long Skeletal Half-Life Problem

Bisphosphonates bind hydroxyapatite at sites of active bone remodeling. In growing bone, those sites are abundant, which means pediatric patients can accumulate proportionally more drug in their skeleton than adults. The estimated terminal half-life of zoledronic acid within bone exceeds 10 years in adults; in children, the distribution may be even wider given rapid bone turnover during growth spurts. A 2013 study in the Journal of Bone and Mineral Research (N=32) confirmed that bisphosphonate "zebra lines" visible on X-ray persist into early adulthood, marking the skeletal record of every infusion cycle.

This persistence has two clinical consequences. First, an adult provider who does not review pediatric infusion records may re-start treatment prematurely. Second, if the underlying condition has remitted (for example, glucocorticoid therapy has ended), continued dosing may suppress remodeling beyond what is safe or necessary.

Who Is Responsible for the Transition?

Responsibility should be shared and documented. The pediatric team creates a written transition summary covering cumulative zoledronic acid dose, infusion dates, DXA Z-scores over time, fracture log, renal function trend, and current calcium and vitamin D status. The adult team reviews that summary before the first appointment and ideally sees the patient at least once jointly with the pediatric provider.

A 2022 survey published in Osteoporosis International found that fewer than 40% of tertiary pediatric centers in Europe had a formal written transition protocol for bisphosphonate-treated patients, a gap that directly predicted treatment interruptions in the 18-to-22-year-old cohort.

Indications That Led to Zoledronic Acid in Children Under 12

Osteogenesis Imperfecta

OI is the most common reason a child under 12 receives IV bisphosphonate therapy. Caused by mutations in COL1A1 or COL1A2 in about 85 to 90% of cases, OI ranges from mild (type I) to perinatally lethal (type II). Types III and IV are those most frequently managed with long-term zoledronic acid. The BRCD2 trial (N=109) compared zoledronic acid to pamidronate in children aged 1 to 17 with OI types I, III, and IV and found comparable improvements in lumbar spine bone mineral density Z-score at 12 months, with zoledronic acid offering the logistical advantage of a once-yearly infusion.

In OI, bisphosphonate therapy does not correct the underlying collagen defect. As patients grow into adulthood, fracture rates may actually decrease with skeletal maturation even without ongoing treatment, particularly in milder OI types. The adult team should reassess whether continued pharmacotherapy is warranted once linear growth has completed.

Glucocorticoid-Induced Osteoporosis

Children receiving prolonged glucocorticoid therapy for conditions such as juvenile idiopathic arthritis, nephrotic syndrome, or solid-organ transplantation are at elevated fracture risk even at low-to-moderate doses. The 2017 American College of Rheumatology guidelines on glucocorticoid-induced osteoporosis recommend bisphosphonate therapy when DXA Z-score falls below -2.0 and glucocorticoid use is expected to continue beyond 3 months. Zoledronic acid 0.05 mg/kg IV once yearly has been studied in this population with measurable improvements in lumbar spine BMD Z-score within 12 months.

When glucocorticoid therapy ends, the bone loss risk trajectory shifts considerably. An adult provider must confirm whether the original indication persists or whether a drug holiday is appropriate.

Secondary Osteoporosis from Other Causes

Cerebral palsy, Duchenne muscular dystrophy, eating disorders, and prolonged immobility can all produce clinically significant bone fragility in children under 12. Zoledronic acid has been used off-label across these conditions. In a 2018 RCT of zoledronic acid in ambulatory children with cerebral palsy (N=34), femoral neck BMD improved by 8.1% vs. 1.2% with placebo at 12 months (P<0.001). The underlying neuromuscular or metabolic condition, not the bisphosphonate exposure alone, determines the adult management plan.

When and How to Begin the Transition

Starting the Conversation Early

Transition should not be an event. It should be a process beginning around age 14 and culminating in a formal handoff at 17 to 18. The Society for Adolescent Health and Medicine recommends that all youth with chronic conditions receive transition preparation at least 2 years before transfer. That advice applies directly here: a patient who has received annual zoledronic acid infusions since age 6 will have 8 or more infusion cycles on record, each requiring documentation and clinical interpretation.

The pediatric team should introduce transition language explicitly at the 14-year-old visit. By 16, the patient should be able to name their condition, recite their treatment history, and describe their symptoms to a new provider independently.

The Pre-Transfer Summary Document

A complete pre-transfer summary for a zoledronic acid patient should include:

• Total number of infusions and dates
• Cumulative weight-adjusted dose in mg/kg
• DXA results at each time point (spine and hip Z-scores; total body less head Z-score for younger children)
• Fracture log with mechanism and site
• Pre-infusion and post-infusion serum creatinine values at each cycle
• 25-OH vitamin D levels and supplementation history
• Calcium intake estimate
• Current underlying diagnosis and disease activity status
• Any adverse events (acute-phase reactions, hypocalcemia episodes, osteonecrosis of the jaw screening)

Without this document, the adult provider is making dose decisions on incomplete pharmacological history.

Renal Function Monitoring at Transfer

Zoledronic acid is contraindicated when creatinine clearance falls below 35 mL/min/1.73 m² per FDA prescribing information. Children with conditions like focal segmental glomerulosclerosis or post-transplant nephropathy may have declining renal function that becomes apparent only as they grow. The FDA label for Reclast (zoledronic acid 5 mg) specifies that renal function must be assessed before each dose and that the drug is not recommended in patients with severe renal impairment.

At the time of transfer, a complete metabolic panel with eGFR calculated using an age-appropriate formula (CKiD U25 equation for patients under 25) should be obtained within 6 weeks of the first adult appointment.

Reassessing the Need for Continued Treatment After Transfer

Not every patient who received zoledronic acid as a child needs to continue it as an adult. The decision should rest on four questions:

1. Is the underlying condition still active and bone-loss producing?
2. What is the current DXA T-score or Z-score, and is it trending toward normal?
3. How many fractures has the patient had in the last 2 years?
4. Has linear growth completed (closed physes on X-ray)?

If the answer to question 1 is no and questions 2 and 3 show a favorable trajectory, a supervised drug holiday is usually appropriate. Bone turnover markers, specifically serum CTX (C-terminal telopeptide) and P1NP (procollagen type 1 N-terminal propeptide), can help determine whether the residual skeletal drug load is still suppressing remodeling. A CTX below 100 pg/mL in a young adult not on bisphosphonates suggests ongoing suppression from prior dosing. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism found that serum CTX normalization after zoledronic acid discontinuation took a median of 18 months in adolescent OI patients, with some patients showing suppression at 36 months.

Using FRAX at Age 18 to 20

Once a patient reaches 18, the FRAX tool becomes applicable as a supplementary risk stratification method. FRAX was validated in adults and is not appropriate for growing children, but it provides a standardized common language between pediatric and adult providers at the time of transfer. The adult provider should input prior bisphosphonate use, current BMD, and any secondary osteoporosis contributors. The International Osteoporosis Foundation notes that FRAX systematically underestimates fracture risk in young adults with high-impact underlying conditions like OI, so clinical judgment must supplement the numerical output.

When to Restart or Continue Treatment in Adults

Some patients will genuinely need ongoing bisphosphonate therapy as adults. Moderate-to-severe OI (types III and IV) rarely resolves, and adult fracture rates in this group remain elevated even after physeal closure. In these patients, transitioning from weight-adjusted pediatric dosing (0.05 mg/kg/year) to the standard adult dose (zoledronic acid 5 mg IV once yearly) is typically appropriate once weight exceeds 100 kg or age reaches 18, whichever comes first, though the pediatric-to-adult dose boundary is not precisely defined in published guidelines. The adult provider should confirm adequate vitamin D (25-OH vitamin D >30 ng/mL) and elemental calcium intake (1,000 to 1,300 mg/day) before each infusion.

Dental and Oral Health Considerations at Transition

Osteonecrosis of the jaw (ONJ) is rare in pediatric bisphosphonate recipients compared with adults, but the cumulative exposure that begins in childhood extends the lifetime risk window. A 2021 systematic review in Oral Oncology (N=21 cases across pediatric bisphosphonate literature) found that ONJ in children was strongly associated with dental extractions performed without prophylactic drug holidays.

The adult care team should obtain a baseline dental panoramic radiograph at the first adult visit and establish a relationship with an oral medicine specialist experienced in bisphosphonate-associated ONJ risk management. The American Dental Association recommends informing dentists of bisphosphonate history before any invasive dental procedure, a habit that pediatric patients must be coached to maintain as they assume self-advocacy responsibilities. ADA guidance recommends discussing the risk vs. Benefit of a drug holiday with the prescribing physician before major oral surgery.

Growth, Physeal Safety, and When Pediatric Concerns End

Zoledronic acid has been associated with transient physeal sclerosis in animal models, but clinically significant growth impairment has not been confirmed in human trials at standard doses. The BRCD2 trial showed no statistically significant difference in height velocity between zoledronic acid and pamidronate arms over 12 months. Growth charts should be maintained through the final pediatric visit, and height velocity should be within 1 standard deviation of expected for bone age at the time of transfer.

Once the growth plates close, physeal safety is no longer a concern. The adult provider can apply standard adult BMD monitoring intervals: DXA every 1 to 2 years for high-risk patients, every 2 to 3 years for patients in remission with normal or near-normal T-scores.

Vitamin D and Calcium Through Transition

Adequate vitamin D and calcium are non-negotiable adjuncts at every stage. Children under 12 require 600 IU of vitamin D daily per the Institute of Medicine, but those with malabsorption (common in celiac disease, inflammatory bowel disease, or post-surgical short gut) may need 2,000 to 4,000 IU daily to maintain 25-OH vitamin D above 30 ng/mL. As patients enter adult care, the Endocrine Society recommends 1,500 to 2,000 IU daily for adults at risk of deficiency, with serum monitoring every 6 to 12 months in the first 2 years post-transfer.

Hypocalcemia is the most common acute adverse effect of zoledronic acid infusion. The FDA label requires pre-infusion calcium repletion and monitoring for several days after infusion. Pediatric patients who experienced post-infusion hypocalcemia should have that documented prominently so adult infusion nurses can anticipate and prevent recurrence.

Coordinating the Adult Team

The adult receiving team should ideally include an endocrinologist or rheumatologist with metabolic bone expertise, a primary care provider, and a pharmacist. For OI patients, a genetics counselor may be appropriate given reproductive implications of collagen mutations.

The first adult appointment should be scheduled no later than 6 months after the last pediatric visit. A gap exceeding 12 months between last pediatric contact and first adult contact is associated with significant treatment interruptions. A 2020 study in the Journal of Adolescent Health (N=412) found that every 3-month delay in transition handoff correlated with a 14% increase in the probability of at least one missed specialty visit in the 24 months post-transfer.

"The transition from pediatric to adult care for patients with bone fragility conditions is not merely administrative. It is a clinical intervention in its own right, and failures at this juncture carry real fracture consequences," wrote Dr. Frank Rauch, a leading researcher in pediatric bone disorders, in a 2016 commentary in the Journal of Musculoskeletal and Neuronal Interactions.

That framing has not changed. Clinicians on both sides of the transition need to treat the handoff as a medical event requiring documentation, direct communication, and patient education.

Patient and Family Education Before Transfer

Parents who have managed their child's infusion schedule for years may struggle to step back. By the time the patient is 16, they should be present in appointments without a parent for at least part of the visit. Specific educational goals before transfer include:

• Understanding the name and dose of their medication
• Knowing when the next infusion is due
• Being able to describe their underlying diagnosis to a new provider
• Knowing to tell any dentist or oral surgeon about bisphosphonate history
• Knowing to report jaw pain, thigh pain, or new-onset groin pain promptly (atypical femoral fracture risk, though rare)
• Understanding that calcium and vitamin D supplements must continue between infusions

Atypical femoral fractures, associated with prolonged bisphosphonate use, are extremely rare in children and adolescents, but cumulative exposure increases lifetime risk. A 2020 FDA Drug Safety Communication confirmed that the risk is duration-dependent and that patients with 5 or more years of bisphosphonate exposure warrant periodic thigh and hip pain screening.

Patients should receive a written summary of their treatment history that they carry to every medical and dental appointment, independent of electronic records availability.